Financings In Brief: Sequana Therapeutics
Executive Summary
Sequana Therapeutics: La Jolla, Calif. genetics R&D firm will receive an additional $2.5 mil. in proceeds from its initial public offering of 2 mil. shares Aug. 1. The additional proceeds, minus underwriting discounts and commissions, come from the sale of a 300,000-share overallotment to Lehman Brothers, the lead underwriter for the IPO. Lehman purchased the 300,000 additional shares of common stock at $9 per share. Total proceeds from the offering are $19.3 mil...